GSK-2838232

second generation HIV maturation inhibitor

Also Known As:

28-Norlup-18-en-21-one, 3-(3-carboxy-3-methyl-1-oxobutoxy)-17-((1R)-2-(((4-chlorophenyl)methyl)(2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-, (3beta)-; GSK2838232

Networked: 2 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Terpenes: 1461
    - Triterpenes: 2493
      - Pentacyclic Triterpenes: 108
        GSK-2838232: 2

Experts

1.	Jeffrey, Jerry: 2 articles (01/2020 - 01/2018)
2.	Jewell, Roxanne C: 2 articles (01/2020 - 01/2018)
3.	Johns, Brian A: 2 articles (01/2020 - 01/2018)
4.	Johnson, Mark: 2 articles (01/2020 - 01/2018)
5.	Xu, Jianfeng: 2 articles (01/2020 - 01/2018)
6.	Benson, Paul: 1 article (01/2020)
7.	DeJesus, Edwin: 1 article (01/2020)
8.	Dumont, Etienne: 1 article (01/2020)
9.	Felizarta, Franco: 1 article (01/2020)
10.	Gan, Jianjun: 1 article (01/2020)

Related Diseases

1.	Infections 01/01/2020 - "Safety, pharmacokinetics, and efficacy of GSK2838232 boosted by cobicistat were evaluated in individuals with HIV-1 infection. " 01/01/2020 - "A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection."
2.	HIV Infections (HIV Infection) 01/01/2018 - "The results of these studies demonstrated a favorable safety and PK profile for GSK2838232 and support its investigation for the treatment of HIV infection."

Related Drugs and Biologics

1.	Cobicistat
2.	Antiviral Agents (Antivirals)